organization · Reporting owner
North Bridge Venture Management V, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lyra Therapeutics, Inc.LYRA · Entity 46837 | 10% owner | May 31, 2023 | June 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lyra Therapeutics, Inc.
Report date May 31, 2023 · Filed June 02, 2023
Jointly reported with NBVM GP, LLC, DAMORE RICHARD A, NORTH BRIDGE VENTURE PARTNERS V A LP, NORTH BRIDGE VENTURE PARTNERS V-B LP, North Bridge Venture Partners VI L P, North Bridge Venture Management VI, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,259,301 |
Reported balance
After 2023-05-31 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-05-31 · Purchase · Acquired 403,858 · Balance 2,259,301 F1: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F2: The reportable securities are owned directly by NBVP V-A. North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,107,370 |
Reported balance
After 2023-05-31 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-05-31 · Purchase · Acquired 197,946 · Balance 1,107,370 F1: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F3: The reportable securities are owned directly by NBVP V-B. NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 2,521,745 |
Reported balance
After 2023-05-31 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2023-05-31 · Purchase · Acquired 1,203,612 · Balance 2,521,745 F1: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F4: The reportable securities are owned directly by NBVP VI. North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Warrant to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2028-11-30 | IndirectSee footnote | 201,929 |
Reported balance
After 2023-05-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-05-31 · Purchase · Acquired 201,929 · Balance 201,929 F1: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F2: The reportable securities are owned directly by NBVP V-A. North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Warrant to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2028-11-30 | IndirectSee footnote | 98,973 |
Reported balance
After 2023-05-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-05-31 · Purchase · Acquired 98,973 · Balance 98,973 F1: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F3: The reportable securities are owned directly by NBVP V-B. NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
| Warrant to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.67 · Expires 2028-11-30 | IndirectSee footnote | 601,806 |
Reported balance
After 2023-05-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-05-31 · Purchase · Acquired 601,806 · Balance 601,806 F1: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F4: The reportable securities are owned directly by NBVP VI. North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors.
F2: The reportable securities are owned directly by NBVP V-A. North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F3: The reportable securities are owned directly by NBVP V-B. NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
F4: The reportable securities are owned directly by NBVP VI. North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2023 Filed Jun 2, 2023 16:15 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseWarrant to purchase Common Stock · Derivative | 601,806 | $0.13 Strike: $2.67 | $75,225.75 |
DisclosureSEC source: 0000899243-23-014352 · doc4.xml · derivative · entry 6 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 601,806 Underlying: Common Stock · 601,806 shares Expires 2028-11-30 F1 · kind: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F4 · ownership.nature: The reportable securities are owned directly by NBVP VI. North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 16:15 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseWarrant to purchase Common Stock · Derivative | 98,973 | $0.13 Strike: $2.67 | $12,371.63 |
DisclosureSEC source: 0000899243-23-014352 · doc4.xml · derivative · entry 5 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 98,973 Underlying: Common Stock · 98,973 shares Expires 2028-11-30 F1 · kind: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F3 · ownership.nature: The reportable securities are owned directly by NBVP V-B. NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 16:15 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseWarrant to purchase Common Stock · Derivative | 201,929 | $0.13 Strike: $2.67 | $25,241.13 |
DisclosureSEC source: 0000899243-23-014352 · doc4.xml · derivative · entry 4 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 201,929 Underlying: Common Stock · 201,929 shares Expires 2028-11-30 F1 · kind: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F2 · ownership.nature: The reportable securities are owned directly by NBVP V-A. North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 16:15 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 1,203,612 | $2.43 | $2,924,777.16 |
DisclosureSEC source: 0000899243-23-014352 · doc4.xml · nonDerivative · entry 3 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,521,745 F1 · kind: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F4 · ownership.nature: The reportable securities are owned directly by NBVP VI. North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 16:15 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 197,946 | $2.43 | $481,008.78 |
DisclosureSEC source: 0000899243-23-014352 · doc4.xml · nonDerivative · entry 2 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,107,370 F1 · kind: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F3 · ownership.nature: The reportable securities are owned directly by NBVP V-B. NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 16:15 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 403,858 | $2.43 | $981,374.94 |
DisclosureSEC source: 0000899243-23-014352 · doc4.xml · nonDerivative · entry 1 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,259,301 F1 · kind: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated May 25, 2023 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F2 · ownership.nature: The reportable securities are owned directly by NBVP V-A. North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 12, 2022 Filed Apr 14, 2022 16:14 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 765,010 | $4.22 | $3,228,342.20 |
DisclosureSEC source: 0000899243-22-014796 · doc4.xml · nonDerivative · entry 3 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,318,133 F1 · kind: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated April 7, 2022 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F4 · ownership.nature: The reportable securities are owned directly by NBVP VI. North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 12, 2022 Filed Apr 14, 2022 16:14 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 527,806 | $4.22 | $2,227,341.32 |
DisclosureSEC source: 0000899243-22-014796 · doc4.xml · nonDerivative · entry 2 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 909,424 F1 · kind: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated April 7, 2022 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F3 · ownership.nature: The reportable securities are owned directly by NBVP V-B. NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| April 12, 2022 Filed Apr 14, 2022 16:14 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 1,076,851 | $4.22 | $4,544,311.22 |
DisclosureSEC source: 0000899243-22-014796 · doc4.xml · nonDerivative · entry 1 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,855,443 F1 · kind: The reportable securities were acquired pursuant to the Securities Purchase Agreement dated April 7, 2022 between the Issuer, North Bridge Venture Partners V-A, L.P. ("NBVP V-A"), North Bridge Venture Partners V-B, L.P. ("NBVP V-B"), North Bridge Venture Partners VI, L.P. ("NBVP VI") and certain other investors. F2 · ownership.nature: The reportable securities are owned directly by NBVP V-A. North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Warrants · Derivative | 13,449 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 39 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 13,449 shares Expires 2030-01-10 F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Warrants · Derivative | 10,322 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 38 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 10,322 shares Expires 2030-01-10 F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Warrants · Derivative | 21,060 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 37 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 21,060 shares Expires 2030-01-10 F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,545,953 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 36 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 44,832 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,186,496 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 35 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 34,408 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries C Convertible Preferred Stock · Derivative | 2,420,729 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 34 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 70,200 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,995,489 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 33 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 57,868 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,531,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 32 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 44,413 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: On May 5, 2020, NBVP VI exercised a warrant to purchase 13,449 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 7,255 of the warrant shares to pay the exercise price and issued the remaining warrant shares to NBVP VI. The Issuer also paid $15.13 to NBVP VI in lieu of a fractional share. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries B Convertible Preferred Stock · Derivative | 3,124,633 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 31 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 90,613 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-4 Convertible Preferred Stock · Derivative | 2,391,895 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 30 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 69,364 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-4 Convertible Preferred Stock · Derivative | 1,835,743 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 29 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 53,236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-4 Convertible Preferred Stock · Derivative | 3,745,346 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 28 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 108,614 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-3 Convertible Preferred Stock · Derivative | 2,929,790 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 27 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 84,963 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-3 Convertible Preferred Stock · Derivative | 2,248,569 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 26 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 65,208 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-3 Convertible Preferred Stock · Derivative | 4,587,608 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 25 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 133,039 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 2,088,772 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 24 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 60,573 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 1,603,102 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 23 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 46,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-2 Convertible Preferred Stock · Derivative | 3,270,702 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 22 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 94,849 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/C Convertible Preferred Stock · Derivative | 1,948,948 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 21 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 56,519 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/C Convertible Preferred Stock · Derivative | 1,495,786 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 20 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 43,377 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/C Convertible Preferred Stock · Derivative | 3,051,758 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 19 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 88,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/B Convertible Preferred Stock · Derivative | 1,647,727 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 18 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 47,783 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/B Convertible Preferred Stock · Derivative | 541,973 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 17 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 15,717 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/B Convertible Preferred Stock · Derivative | 1,105,754 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 16 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 32,066 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/A Convertible Preferred Stock · Derivative | 1,725,090 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 15 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 50,027 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/A Convertible Preferred Stock · Derivative | 567,420 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 14 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 16,455 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/A Convertible Preferred Stock · Derivative | 1,157,670 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · derivative · entry 13 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 33,572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 75,000 | $16.00 | $1,200,000.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 12 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 553,123 F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 57,561 | $16.00 | $920,976.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 11 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 381,618 F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | PurchaseCommon Stock | 117,439 | $16.00 | $1,879,024.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 10 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 778,592 F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 7,255 | $16.00 | $116,080.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 9 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 478,123 F7 · kind: On May 5, 2020, NBVP VI exercised a warrant to purchase 13,449 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 7,255 of the warrant shares to pay the exercise price and issued the remaining warrant shares to NBVP VI. The Issuer also paid $15.13 to NBVP VI in lieu of a fractional share. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Stock | 13,449 | $8.63 | $116,064.87 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 8 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 485,378 F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 5,568 | $16.00 | $89,088.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 7 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 324,057 F6 · kind: On May 5, 2020, NBVP V-B exercised a warrant to purchsae 10,322 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 5,568 of the warrant shares to pay the exercise price and issued the remaining warrant shares to NBVP V-B. The Issuer also paid $9.14 to NBVP V-B in lieu of a fractional share. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Stock | 10,322 | $8.63 | $89,078.86 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 6 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 329,625 F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 11,360 | $16.00 | $181,760.00 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 5 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 661,153 F5 · kind: On May 5, 2020, NBVP V-A exercised a warrant to purchase 21,060 shares of the Issuer's common stock for $16.00 a share, which represents the Issuer's initial public offering price. In connection with the automatic net exercise of the warrant immediately prior to the closing of the Issuer's initial public offering, the Issuer withheld 11,360 of the warrant shares to pay the exercise price and issued the remaining warrant shares to NBVP V-A. The Issuer also paid $12.20 to NBVP V-A in lieu of a fractional share. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | OtherCommon Stock | 21,060 | $8.63 | $181,747.80 |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 4 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 672,513 F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionCommon Stock | 471,929 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 3 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 471,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F4 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners VI, L.P. ("NBVP VI"). North Bridge Venture Management VI, L.P. ("NBVM VI") is the sole general partner of NBVP VI and NBVM GP is the sole general partner of NBVM VI. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP VI. Each of NBVM VI, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionCommon Stock | 319,303 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 2 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 319,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F3 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-B, L.P. ("NBVP V-B"). NBVM V is the sole general partner of NBVP V-B and NBVM GP is the sole general partner of NBVM V. Each of Anderson, a member of the Issuer's board of directors, and D'Amore are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-B. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
| May 05, 2020 Filed May 6, 2020 19:38 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionCommon Stock | 651,453 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012179 · doc4.xml · nonDerivative · entry 1 NBVM GP, LLC · CIK 0001401650 · 10% owner DAMORE RICHARD A · CIK 0001206641 · 10% owner NORTH BRIDGE VENTURE PARTNERS V A LP · CIK 0001138402 · 10% owner NORTH BRIDGE VENTURE PARTNERS V-B LP · CIK 0001138399 · 10% owner North Bridge Venture Partners VI L P · CIK 0001327539 · 10% owner North Bridge Venture Management V, L.P. · CIK 0001297397 · 10% owner North Bridge Venture Management VI, L.P. · CIK 0001590898 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 651,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F2 · ownership.nature: The reportable securities are owned directly by North Bridge Venture Partners V-A, L.P. ("NBVP V-A"). North Bridge Venture Management V, L.P. ("NBVM V") is the sole general partner of NBVP V-A and North Bridge Venture Management GP, LLC ("NBVM GP") is the sole general partner of NBVM V. Each of Edward T. Anderson ("Anderson"), a member of the Issuer's board of directors, and Richard A. D'Amore ("D'Amore") are the managing members of NBVM GP and may be deemed to have shared voting and dispositive power over the shares held by NBVP V-A. Each of NBVM V, NBVM GP, Anderson and D'Amore disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.